Table 1.

Patient characteristics

Patient characteristics	Total cohort
Number of patients	110
Patients from Essen/Münster	25/85
Age	72 [11.1]
Gleason score	8 (range: 5–10)
Metastases locations
Bone	102 (92.7%)
Lymph nodes	84 (76%)
Liver	26 (24%)
Lung/pleura	24 (22%)
History of previous therapies
Abiraterone	92 [83.6%]
Enzalutamide	90 [81.8%]
Docetaxel	92 [80.9%]
Cabazitaxel	29 [26.4%]
Pre- Lu-PSMA therapy blood parameter
Prostate-specific antigen [ng/ml]	231.0 [587.5]
Lactate dehydrogenase [U/l]	317.0 [245.0]
Aspartate aminotransferase [U/l]	33.0 [24.0]
Alanine transaminase [U/l]	19.0 [34.0]
White blood cell count [/μl]	6.0 [2.7]
Hemoglobin [g/dl]	10.5 [2.6]
Platelets [/μl]	234.0 [117.0]
Lu-PSMA therapy
Number of Lu-PSMA cycles	3 (range: 1–12)
Time between PSMA PET and Lu-PSMA start [days]	32 [22]
Average activity per cycle [GBq]	6.7 [1.2]
Cumulated activity [GBq]	21.2 [18.9]

Values are presented as median (inter quartile range) or frequency (percentage of all patients); PSMA prostate-specific membrane antigen, Lu-PSMA ¹⁷⁷Lu-PSMA-617 therapy